Cholic Acid
Phase 3Completed 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Bile Acid Synthesis Defect
Conditions
Bile Acid Synthesis Defect
Trial Timeline
Jan 1, 2010 → Jul 1, 2016
NCT ID
NCT01438411About Cholic Acid
Cholic Acid is a phase 3 stage product being developed by Mirum Pharmaceuticals for Bile Acid Synthesis Defect. The current trial status is completed. This product is registered under clinical trial identifier NCT01438411. Target conditions include Bile Acid Synthesis Defect.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01115582 | Phase 3 | Completed |
| NCT01438411 | Phase 3 | Completed |
Competing Products
13 competing products in Bile Acid Synthesis Defect
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| cisplatin + gemcitabine hydrochloride | Eli Lilly | Phase 3 | 77 |
| exatecan mesylate | Daiichi Sankyo | Phase 2 | 52 |
| Gemcitabine + Cisplatin + Durvalumab | AstraZeneca | Phase 2 | 52 |
| IL-10 | Merck | Phase 2 | 52 |
| aprepitant + gemcitabine hydrochloride + capecitabine + fluorouracil | Merck | Phase 2 | 52 |
| LJN452 + Placebo to LJN452 | Novartis | Phase 2 | 52 |
| Regorafenib | Bayer | Phase 2 | 49 |
| Gemcitabine + Cisplatin + Sorafenib | Bayer | Phase 2 | 49 |
| A3384 | Ipsen | Phase 2 | 49 |
| Cabozantinib | Exelixis | Phase 2 | 49 |
| Cholic acid | Mirum Pharmaceuticals | Phase 3 | 74 |
| Cholbam | Mirum Pharmaceuticals | Pre-clinical | 20 |
| GM-CT-01 + 5-Fluorouracil | Galectin Therapeutics | Phase 2 | 44 |